Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
| Market Cap | $3.60B-8.3% |
| Revenue (ttm) | $682.20M+86.3% |
| Net Income | -$702.23M-765.3% |
| EPS | -$15.19-652.0% |
| Shares Out | 49.31M |
| PE Ratio | n/a |
| Forward PE | 164.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 706,767 |
| Open | $77.09 |
| Previous Close | $77.67 |
| Day's Range | $72.74 - $78.11 |
| 52-Week Range | $53.89 - $91.53 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | $103.43(+41.67%) |
| Earnings Date | Feb 22, 2027 |
About TARS
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating TARS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 22, 2027Earnings report
$TARS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TARS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TARS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TARS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TARS Revenue by Segment
| Product sales, net | $194.57M | 71.52% |
| Selling and marketing | $77.50M | 28.48% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TARS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TARS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TARS
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | $98.60M |
| IWMiShares Russell 2000 ETF | $85.28M |
| VTIVanguard Morningstar Total Stock Market ETF | $83.44M |
| VXFVanguard Extended Market ETF | $32.82M |
| IWOiShares Russell 2000 Growth ETF | $30.72M |
| IBBiShares Biotechnology ETF | $28.19M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TARS’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 4Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 3.58% |
| PJP | Invesco Pharmaceuticals ETF | 3.24% |
| SBIO | ALPS Medical Breakthroughs ETF | 2.21% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.85% |
| BBP | Virtus Biotech ETF | 1.59% |
| HAPS | Harbor Human Capital Factor US Small Cap ETF | 1.34% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.60% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.53% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.37% |
| HELX | Franklin Genomic Advancements ETF | 0.31% |
| PJSM | PGIM Jennison Small-Mid Cap Core Equity ETF | 0.29% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 0.28% |
Weight is the stock’s share of each fund’s holdings.
